Therefore, inhibition of VEGF-A has become a therapeutic strategy for many cancers, including ramucirumab, a monoclonal antibody targeting the major receptor for VEGF-A and has been shown to improve prognosis in second-line treatment of GC (50). This evidence concerns the gene VEGFA and gastric cancer.